TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03720873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib or gefitinib or icotinib
Description: Patients will be treated with erlotinib 150mgQD or gefitinib250mgQD or icotinib 125 mg TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Patients will be treated with Anlotinib 12mg po d1-14 Q21d
Study: NCT03312283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lucentis
Description: intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1205
Description: intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
Study: NCT01383499

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium bromide
Description: inhalation solution administered via Respimat in 3 different doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Description: inhalation solution administered via Respimat in 3 different doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Description: inhalation solution administered via Respimat in 3 different doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Description: inhalation solution administered via Respimat in 3 different doses
Study: NCT00003849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study: NCT00616057

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synergy 1
Description: 8 grams/day during the first week and then 8 grams twice a day during 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: 8 grams/day during the first week and then 8 grams twice a day during 3 months
Study: NCT01449149

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Study: NCT02572882

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: p-inulin
Description: 12 week self-administered treatment phase
Study: NCT04443101

Intervention type: OTHER
Intervention: different types of intracular lens
Description: different types of intracular lens

Intervention type: OTHER
Intervention: different types of intracular lens
Description: different types of intracular lens

Intervention type: OTHER
Intervention: different types of intracular lens
Description: different types of intracular lens
Study: NCT03700073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group (GTVR)
Description: Gait training with a robotic system (CL1Walker) combined with immersion in a Virtual Reality program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group (GT)
Description: Gait training with a robotic system (CL1Walker) alone.
Study: NCT01847469

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced-Cognitive Processing Therapy-C (E-CPT-C)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced-Cognitive Processing Therapy-C (E-CPT-C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01877473

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Study: NCT01452321

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex
Study: NCT04447846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Initiation of treatment will begin with 5 mg/kg/day given in two divided doses. The dose will be increased by 5 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 20 mg/kg/day given.
Study: NCT03932669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: 150-300mg daily dose of nilotinib
Study: NCT04345120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-008
Description: The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-008
Description: The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-008
Description: The subjects were admitted to the clinical trial center two days before the administration period (D-2), fasted for 10 hours overnight on the day before the Administration (D-1), and banned water for 1 hour before the administration. Take sy-009 test drug or placebo immediately before meal (QD is before breakfast, bid is before breakfast and dinner) in the morning of the first day of administration, and deliver it with not more than 200ml warm boiled water. From the day 2 (D2) to the day 7 (D7) before dinner, the oral cavity of the subjects was checked for residual drugs after each administration.
Study: NCT03781999

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Actiful
Description: supplement containing 500 mg orange extract and 200 mg pomegranate actives

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT04016467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic manipulation
Description: High velocity, small amplitude thrust treatment to spine that elicits a neurophysiologic response.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham thoracic treatment
Description: Hand placement on thorax without thrust.
Study: NCT01795573

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cultured Treg cells
Description: Co-culturing of recipient dendritic cells and donor Treg. Treg administration will occur 2 days before the allogeneic stem cell transplant (i.e. day -2 with reference of day 0 as stem cell infusion date).
Study: NCT00819520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Description: Two single doses of oral ivermectin 400 mcg/kg (Days 1 and 8) plus 2 single applications of placebo lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: malathion
Description: Two single applications of malathion 0.5% lotion (Days 1 and 8) plus 2 single doses of placebo tablets
Study: NCT02057523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: Those interested will be started on Acthar 80 units twice weekly for 6 months. Those with minor adverse effects such as weight gain, worsening hypertension, or glucose intolerance will have their doses reduced to 40 unit twice weekly. Those with major adverse effects such as allergy or infection will discontinue the medication. If the primary endpoint of 50% reduction in proteinuria or total proteinuria less than 150mg/day is not reached, therapy may be continued for a total of 12 months.
Study: NCT04342793

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-L1023 1,200mg
Description: ALS-L1023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-L1023 1,800mg
Description: ALS-L1023
Study: NCT02301260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed of Processing Training (SPT)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
Study: NCT03487354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol
Study: NCT02744378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus 0.1%
Description: This group was randomly allocated to receive topical Tacrolimus 0.1% for 3 consecutive weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol 0.05%
Description: This group was randomly allocated to receive topical Clobetasol 0.05% for 3 consecutive weeks
Study: NCT02835833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib will be given twice daily at either 150 mg or 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib will be given twice daily at either 150 mg or 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be given at 15 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be given at 15 mg/kg
Study: NCT03407664

Intervention type: OTHER
Intervention: this field is not applicable
Description: We will not be testing an intervention. Only the long term outcomes of men screened for AAA in England.
Study: NCT02313233

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Umooze
Description: Umooze is consisted of Astragalus radix extracts and soy extracts. Astragalus radix (AR) is the dried root of Astragalus membranaceus Bge. Var. mongholicus and is used as a tonic in the traditional Chinese medicine. According to the reports submitted by the National Cancer institute of American, people who eat soybean products can reduce the incidence rate for prostate cancer. The composition of Umooze is invented by Golden Biotechnology Corp. against prostatic hyperplasia.
Study: NCT04345120

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SY-008 matching placebo
Description: SY-008 matching placebo
Study: NCT02313233

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is consisted of cornstarch and is provided by by Golden Biotechnology Corp.
Study: NCT03392545

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined immune adjuvants and radiation
Description: 24 hours before the radiation, patients will be administrated poly I:C or CAR-T or TCR-T intratumorally and receive granulocyte macrophage colony stimulating factor 5 days after the radiation.
Study: NCT02292927

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Post-intervention arm = Prehabilitation
Description: Introduction of a physical exercise training programme, psychological counselling and smoking cessation advice
Study: NCT00211185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox
Description: Denileukin diftitox will be administered intravenously (IV) at a dosage of 18 micrograms/kilogram/day (ug/kg/d) on Days 1 and 2 of each 21-Day cycle for a total of 6 cycles, with a maximum of 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered IV at a dosage of 750 milligrams/meter squared (mg/m\^2) on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered IV at a dosage of 50 mg/m\^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be administered IV at a dosage of 1.4 mg/m\^2 on Day 3 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered orally at a dosage of 100 mg on Days 3 to 7 of each 21-day cycle for 6 cycles, with a maximum of 8 cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim will be administered at a dosage of 6 mg subcutaneously on Day 4 to help prevent neutropenia. Alternatively, participants received filgrastim 5 ug/kg/d starting on Day 4 and continued until absolute neutrophil count (ANC) was less than 5000/millimeter squared (mm\^2) for 2 days post-nadir.
Study: NCT01466933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsive parenting
Description: On a monthly basis, mothers meet with the peer educator to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development. Mothers practice with their child and are coached by the peer educator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child Development
Description: On a monthly basis, mothers meet with the government worker to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development.
Study: NCT02667197

Intervention type: OTHER
Intervention: Algorithm to determine overdose from opioid abuse
Study: NCT02502123

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention was administered in this study.
Study: NCT03168607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
Study: NCT04617561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic acid
Description: Participants received Ursodeoxycholic acid (13-15mg/kg/d po.)
Study: NCT03852056

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MFP Fluoride toothpaste
Description: Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste
Description: Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
Study: NCT04617561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)
Description: Participants received Methylprednisolone (12mg/d po. in induction and 2-4mg/d in maintenance) combined with Ursodeoxycholic acid (13-15mg/kg/d po.)
Study: NCT02479321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GDT based on noninvasive monitoring
Description: Before entering the operating room, hemodynamic optimization start by optimizing preload with Fluid Challenge according to evidence-based GDT protocols. Once stabilized the cardiovascular system after induction of anesthesia, hemodynamic optimization continue with Mini Fluid Challenge.~In the intraoperative period, hemodynamic optimization is based on maintaining systolic blood pressure and stroke volume. A Mini Fluid Challenge is administered to patients who respond to volume or a vasoactive drug according cardiac index for non-responders.
Study: NCT02596867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propanolol
Description: Participants will take 1.5 mg/kg/day propranolol, twice daily for 3 weeks until surgical resection of the breast tumor is performed
Study: NCT02479321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: System ClearSight® and Platform EV Clinic 1000®
Description: Hemodynamic control is held by non-invasive continuous monitoring techniques (system ClearSight® and Platform EV Clinic 1000®). Monitored variables: blood pressure, heart rate, oxygen saturation, cardiac output, cardiac index, stroke volume and stroke volume index.
Study: NCT03390218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy Assistance Online
Description: protocoled on-line educational modules, with brief therapist interaction and practice support with a mobile app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Individual and group therapy, generic in nature
Study: NCT01927926

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey-protein & polydextrose snack
Description: Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control snack
Description: Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
Study: NCT02218294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX4161
Study: NCT03775889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gardening
Description: Assist with planting and maintaining the school garden, as well as observe the school garden curriculum and dietary assessment protocols
Study: NCT04727892

Intervention type: PROCEDURE
Intervention: epilepsy surgery
Description: Surgical procedures were individually designed according to the presurgical evaluation findings. Standard epilepsy surgery procedures were applied. Generally, surgical procedures were divided into curative and palliative surgery. Curative surgery included resection and disconnection of the epileptogenic zone. Palliative surgery included corpus callosotomy for bilateral synchronous onset and multiple subpial transections for epileptic foci located in the eloquent cortex. For widespread epileptogenic zones, multiple surgical techniques were combined.
Study: NCT02021097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg
Description: Tablet, orally, opd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel 150 mcg and Ethinyl Estradiol 30 mcg
Description: Tablet, orally, opd
Study: NCT01681173

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber
Description: 200ml drinks enriched with 7,5g of fiber (90% insoluble fiber, 10% soluble fiber), BID, over 24 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 200ml Placebo, BID, over 24 months
Study: NCT04894487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THE USE OF BABY MOBILE ACCOMPANIED WITH BRAHMS LULLABY
Description: Using of baby mobile and listening Brahms Lullaby during sternum dressing process
Study: NCT02244021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRENTUXIMAB VEDOTIN
Description: Patients with FDG-PET positive after IGEV will be treated with brentuximab vedotin as followed: 1.8 mg/kg every 3 weeks as a 30-minute outpatient IV infusion for a total of 4 cycles of treatment~Growth factors may be used at the discretion of investigators but are not routinely advised.~Patients with FDG-PET negative after brentuximab vedotin treatment will be addressed to high dose chemotherapy followed by ASCT.
Study: NCT02796157

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with Absorb everolimus-eluting bioresorbable vascular scaffold
Description: Patients allocated to this arm will undergone PCI with Absorb everolimus-eluting bioresorbable vascular scaffold. It will be allowed to used multiple stents for a long coronary lesion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI with Xience everolimus-eluting metallic stent
Description: Patients allocated to this arm will undergone PCI with Xience everolimus-eluting metallic stent. It will be allowed to used multiple stents for a long coronary lesion.
Study: NCT03270397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic course The group- theory and practice
Description: Active participation in the course The group- theory and practice.
Study: NCT01576250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unilateral lower limb suspension
Description: This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
Study: NCT00122460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)
Description: Subjects in will receive initial dose of 400 mg/m\^2 cetuximab (over 2 hours) followed by weekly doses of 250 mg/m\^2 (over 1 hour). All doses will be given by intravenous (IV) infusion. Subjects will receive either Cisplatin (100 mg/m\^2 on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (Area under the curve (AUC) 5 IV on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum (Cisplatin or Carboplatin) + 5-FU
Description: All doses will be given by IV infusion. Subjects will receive either Cisplatin (100 mg/m\^2 on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) + 5-FU (1000 mg/m\^2 continuous IV from day 1 to day 4) every 3 weeks
Study: NCT01115751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2780301
Description: Administered orally, daily for two 28-day cycles.~Starting dose is 100mg. The dose will be subsequently increased to 200mg, 300mg, 400mg, 500mg, and 600mg if no dose limiting toxicity is observed at the prior dose levels. Patients who, in the opinion of the investigator, demonstrate clinical benefit may receive treatment beyond two cycles until disease progression.
Study: NCT01947972

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Tailored protein fortification
Description: 4-4.5g of protein/kg/d